In Vivo Activity of Posaconazole againstMucorspp. in an Immunosuppressed-Mouse Model
Open Access
- 1 July 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (7) , 2310-2312
- https://doi.org/10.1128/aac.46.7.2310-2312.2002
Abstract
The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 μg/ml and 0.25 to 8 μg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 μg/ml. At twice-daily doses of ≥15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.Keywords
This publication has 19 references indexed in Scilit:
- In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazoleJournal of Antimicrobial Chemotherapy, 2001
- Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazoleJournal of Antimicrobial Chemotherapy, 2001
- Treatment of 21 Cases of Invasive Mucormycosis with Amphotericin B Colloidal DispersionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2001
- Cluster of Pulmonary Infections Caused byCunninghamella bertholletiaein Immunocompromised PatientsClinical Infectious Diseases, 2000
- Zygomycosis in the 1990s in a Tertiary-Care Cancer CenterClinical Infectious Diseases, 2000
- Disseminated Zygomycosis in a Neutropenic Patient: Successful Treatment with Amphotericin B Lipid Complex and Granulocyte Colony-Stimulating FactorClinical Infectious Diseases, 1997
- Survival factors in rhino-orbital-cerebral mucormycosisSurvey of Ophthalmology, 1994
- Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drugJournal of Antimicrobial Chemotherapy, 1994